By: IPP Bureau
Last updated : September 29, 2026 2:54 pm
Acquired Tanfac Industries, Jayhawk Fine Chemicals and Bliss GVS Pharma in last 4 years
Anupam Rasayan India Limited has completed a series of strategic acquisitions to build a diversified, vertically integrated life sciences and global Contract Development and Manufacturing Organisation (CDMO) platform.
By consolidating Bliss GVS Pharma, Tanfac Industries, and Jayhawk Fine Chemicals, the combined group establishes a massive financial footprint, reaching an estimated pro-forma revenue exceeding Rs. 4,000 crore with a consolidated EBITDA of approximately Rs. 834 crore. The pro-forma revenue comprises approximately Rs. 1,676 crore from Anupam Rasayan standalone, Rs. 711 crore from Tanfac Industries, Rs. 722 crore from Jayhawk Fine Chemicals and Rs. 927 crore from Bliss GVS Pharma.
The three strategic acquisitions have each been undertaken with a distinct objective of strengthening access to critical raw materials, establishing a global manufacturing footprint and, now, extending the value chain into finished dosage formulations.
This corporate evolution represents a structural shift from custom chemical synthesis toward an end-to-end pharmaceutical value chain. Each acquired entity functions as a distinct pillar in this lifecycle:
Tanfac Industries (Backward Integration): Acquired in 2022, this specialty fluorides manufacturer secures Anupam Rasayan’s upstream raw material pipeline. It guarantees steady access to critical inputs like hydrofluoric acid and potassium fluoride, mitigating supply chain risks. Tanfac contributes Rs. 711 crore to the pro-forma revenues.
Jayhawk Fine Chemicals (Nearshoring & Advanced Chemistry): Bought in early 2026 for an enterprise value of approximately $134–150 million, Kansas-based Jayhawk provides a vital manufacturing base inside the United States. Specialising in high-purity processes and complex custom synthesis, Jayhawk brings cross-selling opportunities across regulated western markets and accounts for Rs. 722 crore of the consolidated revenue.
Bliss GVS Pharma (Forward Integration): Completed in September 2026 for Rs. 1,750 crore, this acquisition adds finished dosage formulations to the ecosystem. Bliss GVS operates six USFDA and EU-GMP compliant facilities in Maharashtra. It provides ₹927 crore in revenue and an invaluable platform for downstream growth.
The core synergy of this Rs. 4,000+ crore platform rests on cross-geographical operational optimization. Bliss GVS currently operates at a mere 30% capacity utilization. By routing its traditional Key Starting Materials (KSMs) and advanced intermediates into Bliss GVS's underutilized formulation infrastructure, Anupam Rasayan plans to scale utilization to 70–80%. Backed by institutional funding from Bain Capital, the consolidated Anupam Rasayan Platform positions itself to provide global innovators with end-to-end chemistry solutions from raw molecules to finished medicines.